Literature DB >> 35764740

The status of tumor mutational burden and immunotherapy.

Valsamo Anagnostou1, Alberto Bardelli2,3, Timothy A Chan4,5, Samra Turajlic6,7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35764740     DOI： 10.1038/s43018-022-00382-1

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


× No keyword cloud information.
  1 in total

1.  Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project.

Authors:  D M Vega; L M Yee; L M McShane; P M Williams; L Chen; T Vilimas; D Fabrizio; V Funari; J Newberg; L K Bruce; S-J Chen; J Baden; J Carl Barrett; P Beer; M Butler; J-H Cheng; J Conroy; D Cyanam; K Eyring; E Garcia; G Green; V R Gregersen; M D Hellmann; L A Keefer; L Lasiter; A J Lazar; M-C Li; L E MacConaill; K Meier; H Mellert; S Pabla; A Pallavajjalla; G Pestano; R Salgado; R Samara; E S Sokol; P Stafford; J Budczies; A Stenzinger; W Tom; K C Valkenburg; X Z Wang; V Weigman; M Xie; Q Xie; A Zehir; C Zhao; Y Zhao; M D Stewart; J Allen
Journal:  Ann Oncol       Date:  2021-10-01       Impact factor: 32.976
  1 in total
  1 in total

1.  CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma.

Authors:  Zhang-Wei Hu; Wei Sun; Yi-Hui Wen; Ren-Qiang Ma; Lin Chen; Wen-Qing Chen; Wen-Bin Lei; Wei-Ping Wen
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.